Therefore, the anti-tumor immune response of PD-L1 expression on macrophages is different based on the tumor type and tumor development stage, so it is still controversial whether macrophage-expressed PD-L1 can be used as a biomarker to predict the efficacy of ICI therapy. This evidence concerns the gene CD274 and neoplasm.